University of Mississippi

eGrove
Faculty and Student Publications

Pharmacy, School of

10-2-2020

Safety and molecular-toxicological implications of cannabidiolrich cannabis extract and methylsulfonylmethane coadministration
Kristy R. Kutanzi
University of Arkansas for Medical Sciences

Laura E. Ewing
University of Arkansas for Medical Sciences

Charles M. Skinner
University of Arkansas for Medical Sciences

Charles M. Quick
University of Arkansas for Medical Sciences

Stefanie Kennon-McGill
University of Arkansas for Medical Sciences

See next page for additional authors

Follow this and additional works at: https://egrove.olemiss.edu/pharmacy_facpubs

Recommended Citation
Kutanzi, K. R., Ewing, L. E., Skinner, C. M., Quick, C. M., Kennon-McGill, S., McGill, M. R., Walker, L. A.,
ElSohly, M. A., Gurley, B. J., & Koturbash, I. (2020). Safety and Molecular-Toxicological Implications of
Cannabidiol-Rich Cannabis Extract and Methylsulfonylmethane Co-Administration. International Journal
of Molecular Sciences, 21(20), 7808. https://doi.org/10.3390/ijms21207808

This Article is brought to you for free and open access by the Pharmacy, School of at eGrove. It has been accepted
for inclusion in Faculty and Student Publications by an authorized administrator of eGrove. For more information,
please contact egrove@olemiss.edu.

Authors
Kristy R. Kutanzi, Laura E. Ewing, Charles M. Skinner, Charles M. Quick, Stefanie Kennon-McGill, Mitchell R.
McGill, Larry A. Walker, Mahmoud A. Elsohly, Bill J. Gurley, and Igor Koturbash

This article is available at eGrove: https://egrove.olemiss.edu/pharmacy_facpubs/61

International Journal of

Molecular Sciences
Article

Safety and Molecular-Toxicological Implications
of Cannabidiol-Rich Cannabis Extract and
Methylsulfonylmethane Co-Administration
Kristy R. Kutanzi 1 , Laura E. Ewing 1,2,3 , Charles M. Skinner 1,3,4 , Charles M. Quick 5 ,
Stefanie Kennon-McGill 1,4 , Mitchell R. McGill 1,2,4 , Larry A. Walker 6,7 ,
Mahmoud A. ElSohly 6,7,8 , Bill J. Gurley 4,6 and Igor Koturbash 1,4, *
1

2
3
4
5
6
7
8

*

Department of Environmental and Occupational Health, University of Arkansas for Medical Sciences,
Little Rock, AR 72205, USA; Kristy.kutanzi@gmail.com (K.R.K.); leewing@uams.edu (L.E.E.);
cmskinner@uams.edu (C.M.S.); skennonmcgill@uams.edu (S.K.-M.); mmcgill@uams.edu (M.R.M.)
Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences,
Little Rock, AR 72205, USA
Department of Biochemistry, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Center for Dietary Supplements Research, University of Arkansas for Medical Sciences,
Little Rock, AR 72205, USA; bjgurley@olemiss.edu
Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA;
quickcharlesm@uams.edu
National Center for Natural Products Research, University of Mississippi, Oxford, MS 38677, USA;
lwalker@olemiss.edu (L.A.W.); melsohly@olemiss.edu (M.A.E.)
ElSohly Laboratories, Inc. (ELI), Oxford, MS 38655, USA
Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi,
Oxford, MS 38677, USA
Correspondence: ikoturbash@uams.edu; Tel.: +1-501-526-6638

Received: 28 September 2020; Accepted: 18 October 2020; Published: 21 October 2020




Abstract: Cannabidiol (CBD) is a biologically active, non-psychotropic component of Cannabis sativa
whose popularity has grown exponentially in recent years. Besides a wealth of potential health
benefits, ingestion of CBD poses risks for a number of side effects, of which hepatotoxicity and
CBD/herb-drug interactions are of particular concern. Here, we investigated the interaction potential
between the cannabidiol-rich cannabis extract (CRCE) and methylsulfonylmethane (MSM), a popular
dietary supplement, in the mouse model. For this purpose, 8-week-old male C57BL6/J mice
received MSM-containing water (80 mg/100 mL) ad libitum for 17 days. During the last three days
of treatment, mice received three doses of CRCE administered in sesame oil via oral gavage
(123 mg/kg/day). Administration of MSM alone did not result in any evidence of liver toxicity and
did not induce expression of mouse cytochrome P450 (CYP) enzymes. Administration of CRCE
did produce significant (p < 0.05) increases in Cyp1a2, Cyp2b10, Cyp2c29, Cyp3a4, Cyp3a11, Cyp2c65,
and Cyp2c66 messenger RNA, however, this effect was not amplified by MSM/CRCE co-treatment.
Similarly, no evidence of liver toxicity was observed in MSM/CRCE dosed mice. In conclusion,
short-term MSM/CRCE co-administration did not demonstrate any evidence of hepatotoxicity in the
mouse model.
Keywords: cannabidiol; cytochrome P450; dietary supplements; hemp extract; hepatotoxicity;
herb-drug interaction; methylsulfonylmethane; safety; toxicity
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1. Introduction
Cannabidiol (CBD), a biologically active, non-psychotropic component of Cannabis sativa,
has gained significant inroads into the US market over the last year with seemingly endless health claims
positioning it as a proverbial panacea for treating stress and pain, boosting energy, enhancing circulation,
and even curing arthritis and cancer [1–3]. CBD is a major component of Epidolex® , a drug
indicated for the treatment of drug-resistant epileptic seizures associated with some rare pediatric
syndromes [4–6]. Furthermore, recent studies indeed indicate significant potential CBD may have
on social anxiety disorder and symptomatic improvement in schizophrenia (reviewed in [4–6])
Yet these promises may come at a cost, with a range of adverse side effects noted in vivo and
among clinical trials, including diarrhea, vomiting, pneumonia, sedation, and somnolence [4–6].
Furthermore, cardiovascular, neurological, reproductive, embryo-fetal, gastrointestinal, and liver
toxicity have been documented subsequent to CBD use at higher doses [5,7–14]. To add to these
complications, numerous studies have demonstrated that CBD possesses a significant potential for
drug interactions [15–19].
Among side effects associated with higher dose CBD ingestion, the risk for hepatotoxicity is a
major concern [20]. For instance, plasma levels of liver aminotransferases were greater than three
times the upper limit of normal in patients taking valproate while being treated with Epidiolex® ,
a purified CBD-containing drug used to treat some rare forms of pediatric refractory epilepsy [16,17,21].
Recent findings have shown that cannabidiol-rich cannabis extract (CRCE) given concomitantly with
acetaminophen (APAP), one of the most common over-the-counter medications, exacerbates CBD
hepatotoxicity, leading to sinusoidal obstruction syndrome-like liver injury and mortality in the mouse
model [15]. These effects were associated with ingestion of high (therapeutic range) doses of CBD,
however, the widespread and relatively indiscriminate distribution of CBD-containing products in the
supplement market, and the potential inter-individual variability in response to CBD raises concerns
as to co-ingestion of CBD and CBD-containing products with prescription and nonprescription drugs.
Dietary supplements (DSs) represent a large group of food items whose regulatory landscape is
defined by the Dietary Supplement Health and Education Act (DSHEA 1994). According to DSHEA,
pre-market safety assessments for DSs are not required and, while most DSs pose no serious concerns
for toxicity, rare cases of herb-induced hepato- and cardiotoxicity as well as clinically relevant herb-drug
interactions argue for a more cautious approach to assessing DS safety [22–24].
According to recent polls, up to 70% of U.S. adults took at least one DS within the last 12 months.
While it is difficult to realistically assess the current market for CBD and CBD-containing products,
their increased popularity suggests that the fraction of U.S. consumers ingesting these products is
substantial. Therefore, the probability for concomitant ingestion of CBD with other DSs is very likely,
and the potential for CBD–DS interactions necessitates thorough investigation.
In this regard, methylsulfonylmethane (MSM), a natural organosulfur compound, is of particular
interest. MSM is found in a wide range of foods, including certain vegetables, fruits, grains,
and beverages. Also known as dimethyl sulfone, MSM has become a popular DS, largely for its
anti-oxidative and anti-inflammatory properties with some studies indicating that ~10% of supplement
users regularly ingest MSM [25]. Numerous patents claiming positive health benefits ranging from
stress and pain relief to increased energy and metabolism, enhanced circulation, and improved wound
healing [26–29], along with publications showing potential clinical benefit in arthritis and other
inflammatory disorders [30,31], have been exploited in marketing of MSM as a popular supplement.
MSM is readily absorbed in the small intestine of both rodents and humans and is characterized
by rapid distribution throughout tissues, including the small intestine and liver [32]. Studies indicate
that MSM exerts its antioxidant and free-radical scavenging properties by targeting the transcriptional
activity of nuclear factor kappa-light-chain enhancer of activated B cells (NF-kB), signal transducers
and activators of transcription (STAT), p53, and nuclear factor (erythroid-derived 2)-like 2 (Nrf2)
(reviewed in [25]). However, whether or not MSM is capable of affecting cytochrome P450 (CYP)
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enzymes in the liver remains unknown. Furthermore, while numerous studies indicate the safety of
MSM even at high doses, the potential for MSM-drug/herb interactions remains unexplored.
Therefore, the aim of this study was to investigate whether MSM administration affects the
expression of major CYP isoforms and if concurrent use of MSM with CRCE results in MSM–CRCE
interactions and/or sensitization to CRCE-induced liver injury.
2. Results
2.1. Phytocannabinoid Characterization of CRCE
CRCE phytochemical characterization results are presented in Table 1. This phytocannabinoid
composition is comparable to those of CRCEs used in previous studies, as well as in products
currently on the U. S. market [13–15,33]. Other measurements were as follows: loss on drying—0.32%;
heavy metals: lead, mercury, cadmium, and arsenic—not detected; aflatoxins: AFB1 , AFB2 , AGF1 ,
and AFG2 —not detected; Escherichia coli—absent; Salmonella—absent; Total Aerobic Microbial Count
(TAMC)—<10 cfu/g; Total Yeast and Mold Count (TYMC)—<10 cfu/g; all of which are below USP
acceptable levels for non-sterile oral preparations.
Table 1. Phytocannabinoid characterization of cannabidiol-rich cannabis extract (CRCE).
Phytoconstituent

Levels, %

Cannabidiol

57.9

Cannabichromene

2.03

∆9 -tetrahydrocannabinol

1.69

Cannabigerol

1.07

∆8 -tetrahydrocannabinol

<0.01

Tetrahydrocannabivarin

<0.01

Residual Solvent

<0.05

2.2. Anatomical Examination and Physiological Parameters
Throughout the study there were no signs of overt toxicity. Gross anatomical examination
upon termination found no visual abnormalities in the liver, kidney, or heart. Although there
were no statistically significant differences in body weight between groups, liver-to-body weight
ratios, in agreement with previous studies, were increased in mice treated with CRCE or
MSM/CRCE (Figure 1A,B). No significant differences in kidney- and heart-to-body weight ratios
were observed (Figure 1C,D).
No significant differences were observed in food or water consumption between any of the groups
throughout the experiment (data not shown).
2.3. Histological Findings
Histopathological assessment identified no evidence of necrotic, apoptotic, hemorrhagic,
or inflammatory events in experimental mice (Figure 2).
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Figure 1. Physiological parameters in response to methylsulfonylmethane (MSM), CRCE, or
MSM/CRCE administration in C57BL6/J mice. (A) Body weight change, (B) liver-to-body weight,
(C) kidney-to-body weight, and (D) heart-to-body weight ratios. Data are presented as mean ± SD
(n = 6–8). * indicates a significant difference (p < 0.05), and ** indicates a significant difference (p < 0.01),
as calculated with a two-way ANOVA and Bonferroni post-hoc test. MSM—methylsulfonylmethane,
CRCE—cannabidiol-rich cannabis extract.

Figure 2. Effects of MSM, CRCE, or MSM/CRCE on liver morphology. (A) vehicle (sesame oil);
(B) MSM; (C) CRCE; (D) MSM/CRCE. Magnification: ×40. MSM—methylsulfonylmethane,
CRCE—cannabidiol-rich cannabis extract.

Int. J. Mol. Sci. 2020, 21, 7808

5 of 14

2.4. Clinical Biochemistry
Analysis of clinical biomarkers of liver injury revealed no MSM- or CRCE- associated elevations
in plasma alanine- and aspartate-aminotransferases (ALT and AST, respectively), nor in total bilirubin
(Figure 3A–C). Decreased alkaline phosphatase (ALP) levels were noted in the plasma of CRCE-treated
animals, with no significant difference observed between mice treated with MSM/CRCE compared
to CRCE alone (Figure 3D). Also, there were no measurable differences in circulating liver-specific
miR-122, a novel sensitive biomarker of liver injury (Figure 3E).

Figure 3. Effects of MSM, CRCE, or MSM/CRCE on plasma biomarkers of liver injury. (A) alanine
aminotransferase, ALT; (B) aspartate aminotransferase, AST; (C) total bilirubin; (D) alkaline phosphatase
(ALP); (E) miR-122. Data are presented as mean ± SD (n = 6–8). * indicates a significant difference
(p < 0.05), and ** indicates a significant difference (p < 0.01), as calculated with a two-way ANOVA and
Bonferroni post-hoc test. MSM—methylsulfonylmethane, CRCE—cannabidiol-rich cannabis extract.

2.5. Cytochrome P450 Expression
Many compounds, regardless of their effect on liver morphology, can have major implications on
liver function. To determine if MSM alone or in combination with CRCE could affect the expression of
liver drug metabolizing enzymes at administered doses, we evaluated a panel of mouse CYP isoforms
(Figure 4).
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Figure 4. Effects of administration of MSM, CRCE, or MSM/CRCE on intrahepatic expression of
cytochrome P450s. Livers were collected 24 h after the last gavage and gene expression was measured
using the quantitative real-time (qRT) PCR. Data was analyzed by two-way ANOVA with Bonferroni
post-test and presented as mean ± SD fold change from vehicle (n = 6–8), with * as p < 0.05; ** as p < 0.01,
and *** as p < 0.001. MSM—methylsulfonylmethane, CRCE—cannabidiol-rich cannabis extract.

MSM alone did not affect the hepatic expression of any of the nine investigated CYPs. However,
consistent with previous findings, administration of CRCE for three consecutive days increased
mRNA levels for seven CYP genes, with Cyp2b10 being most affected (~eight-fold increase) (Figure 4).
Interestingly, no induction of Cyp2e1 was observed, an isoform previously reported to be up-regulated
shortly after CRCE administration [13]. The expression of Cyp2d22, an isoform considered non-inducible,
remained unaffected.
Co-administration of MSM with CRCE produced no additional changes in mRNA, as no significant
differences were observed between the CRCE and MSM/CRCE experimental groups. These findings
suggest that several key Phase I metabolic pathways in the liver may be compromised by CRCE,
however, MSM itself does not affect hepatic CYP expression nor does it influence CRCE-associated
CYP induction.
2.6. Glutathione Measurement
Finally, we evaluated the effect of MSM/CRCE co-administration on the synthesis of hepatic
glutathione. The toxicity of xenobiotics is buffered by glutathione, which plays a critical role in
protecting cells from both oxidative damage and electrophilic xenobiotic metabolites. Previous studies
have indicated that MSM can increase hepatic glutathione synthesis, while administration of high
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CRCE doses were associated with pro-oxidative responses [13,34]. Therefore, it was important to
evaluate how co-administration of CRCE with MSM might affect glutathione synthesis.
Consistent with previous findings, administration of MSM resulted in modest increases in
glutathione, while CRCE alone produced slight reductions in total intrahepatic glutathione (Figure 5A).
Furthermore, total glutathione was nearly two-fold higher in MSM/CRCE mice compared to CRCE
alone, suggesting the CRCE did not negatively regulate MSM-associated induction of intrahepatic
glutathione synthesis. Also, several key enzymes involved in different stages of glutathione synthesis
(e.g., Gclm, Gpx1, and Gsr) were unaffected by concomitant ingestion of MSM and CRCE (Figure 5B–D).

Figure 5. Effects of MSM, CRCE, or MSM/CRCE on intrahepatic synthesis of glutathione and the
expression of genes associated with the synthesis of glutathione. (A) Intrahepatic concentrations of
total glutathione; (B–D) mRNA levels of (B) Gclm, (C) Gpx1, and (D) Gsr in the mouse livers 24 h after
the last dose of CRCE. Gene expression was measured using quantitative real-time (qRT) PCR. Data
was analyzed by two-way ANOVA with Bonferroni post-test and are presented as mean ± SD fold
change from vehicle (n = 6–8), with * as p < 0.05.

3. Discussion
CBD and CBD-containing products are currently on the rise throughout healthcare markets
worldwide. Despite its high popularity among consumers, knowledge regarding the negative health
effects of CBD-containing products remains limited. Accumulating evidence, however, indicates that
CBD, when administered at clinically relevant doses, possesses significant potential for hepatotoxicity
as well as for interactions with various conventional medications. In our previous studies, we have
investigated the hepatotoxic potential of CRCE, either alone or when co-administered with another
potent hepatotoxicant—APAP [13,15]. Therefore, the present study was designed to explore the
potential interaction between CRCE and MSM—a popular DS on the U. S. market—that, due to their
widespread usage, may overlap in the treatment of various ailments.
Ingestion of MSM itself resulted in no overt toxicological responses, including hepatotoxicity,
among experimental mice. This finding is in line with previously conducted studies as well as
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its Generally Recognized as Safe (GRAS) status attained in 2007 [35]. Similarly, there was no
histopathological evidence of liver injury in mice gavaged with CRCE, nor with the combination of
MSM and CRCE as determined by plasma aminotransferases, bilirubin, and miR-122.
At the same time, administration of CRCE or CRCE/MSM caused a significant increase in
the liver-to-body weight ratio in mice. This corroborated the findings of other animal studies
examining the effects of CBD or CRCE alone [12,13], or in combination with other hepatotoxicants [15].
Xenobiotic-induced increase in liver weight and liver-to-body weight ratio is not a rare finding in rodent
models and is not necessarily a prerequisite of liver injury (especially, when other more reliable markers
of liver injury are absent) and may be considered an adaptive response. Such adaptive responses
may, in turn, be triggered by robust induction of drug metabolizing enzymes, especially Phase I
enzymes such as CYPs [36]. Indeed, in this study, CRCE caused a significant increase in the mRNA
levels of seven out of nine mouse CYP enzymes. For some like Cyp2b10, which is homologous to
human CYP2B6, the increase was substantial, reaching nearly 10-fold. This finding is of particular
importance, since tissue harvest occurred 24 h after the last CRCE dose. Taking into account the higher
metabolic rates of mice, this suggests CRCE has prolonged effects on hepatic drug metabolizing enzyme
activity. Such CYP-associated increases in liver weight are usually adaptive responses, serving a role of
metabolism enhancement and detoxification, and often resolve shortly after xenobiotic exposure ceases.
The prolonged ingestion of a given xenobiotic may, however, lead to decompensation of adaptive
responses and result in hepatotoxicity. Interestingly, most clinical cases of hepatotoxicity associated
with the CBD in the form of the drug Epidiolex® were due to its prolonged intake and rarely occurred
during the first weeks of treatment [21].
Out of seven CYP enzymes whose expression was induced by CRCE, of particular interest is
Cyp2b10, a mouse enzyme homologous to human CYP2B6. In CRCE-treated groups, its expression
reached nearly 8–10-fold compared to vehicle-treated or MSM-only animals. This data is in agreement
with findings within the B6C3F1 mouse strain, in which Cyp2b10 was the most up-regulated CYP
gene after both single and repeated dosing with CRCE [13]. This CYP isoform is known to play a key
role in the metabolism of prescription drugs, such as cyclophosphamide, ketamine, and bupropion.
Furthermore, CYP2B6 together with CYP3A4 are central to the metabolism of clobazam, a common
anti-seizure medication used in the treatment of many forms of epilepsy. Here, we demonstrate that
CRCE, besides eliciting a robust upregulation of Cyp2b10 mRNA, increased expression of two CYP3A4
mouse homologs—Cyp3a4 and Cyp3a11. Clinical trials confirm this finding, demonstrating higher
serum concentrations of N-desmethylclobazam, the active metabolite of clobazam, when the latter is
co-administered with CBD (Epidiolex® ) [24]. Though this elevation of N-desmethylclobazam may also
be attributable to inhibition of CYP2C19, contributions of CYP3A and CYP2B6 induction have also been
recognized [37,38]. This ability to serve as a substrate for multiple CYPs suggests that CBD-containing
products may have a significant interaction potential with other drugs besides clobazam.
MSM is rapidly absorbed from the gastrointestinal tracts of both humans and rodents [39].
The exact metabolic fate of MSM is not fully understood, however, its tissue distribution and liver
accumulation as well as formation by hepatic microsomes have been reported [40]. Studies in rats
further demonstrate that up to 80% of MSM is excreted unchanged [41]. Here, we demonstrated that
MSM caused no measurable changes in the expression of a panel of mouse hepatic Cyps. Furthermore,
pre-treatment with MSM for two weeks did not affect CRCE-associated CYP induction, suggesting a
rather inert nature of MSM in the mouse liver.
Despite the liver’s seemingly minor role in MSM clearance, an indirect potential for an MSM/CRCE
interaction cannot be dismissed. For instance, a recent report indicated an important role Cyp2c29,
another CYP affected by CRCE in this study, plays in liver injury [42]. This homolog of human
CYP2C8 and CYP2C9 was found to be continuously down-regulated during liver injury. In contrast,
reversal of Cyp2c29 expression in APAP- and CCl4 -induced hepatotoxicity (two common models
of liver injury), resulted in suppression of pro-inflammatory signaling and cytokine production by
targeting NF-kB pathway [42]. Interestingly, similar anti-inflammatory effects associated with NF-kB
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inhibition were reported for MSM [43,44]. These findings may have a significant therapeutic value
and further investigations of the MSM/CRCE interaction potential and its effects on NF-kB signaling
pathway are clearly warranted.
Previous studies have demonstrated that high doses of CBD/CRCE can deplete intrahepatic
glutathione and its synthesis [13,15]. The latter plays a critical role in protecting cells from oxidative
damage and the toxicity of xenobiotic electrophiles by maintaining redox homeostasis. MSM has
been previously reported to effectively modulate synthesis of glutathione in experimental models [34].
The exact mechanism(s) underlying this modulatory effect remain unknown, but by serving as an
alternate source of sulfate for the sulfation and detoxification of various compounds, MSM may spare
cysteine for the synthesis of glutathione [45–47]. Therefore, it is critical to understand whether or not
the ability of MSM to regulate glutathione will be hampered by concurrent ingestion of other DSs,
particularly the popular glutathione-depleting CBD-containing products. Importantly, we demonstrate
that mice treated with MSM and subsequently challenged with CRCE exhibited a nearly two-fold
increase in hepatic glutathione levels, compared to CRCE alone. Furthermore, the potential of
MSM to mitigate toxin-induced liver damage, such as with carbon tetrachloride [48], paraquat [45],
or APAP [46], suggests that MSM can serve as a valuable hepatoprotective agent, including in cases of
CBD/CRCE-induced liver injury.
In conclusion, we report that concurrent short-term administration of MSM with CRCE is not
hepatotoxic in an experimental mouse model. Furthermore, the potential for an MSM/CRCE interaction
appears low based upon the lack of CYP modulation by MSM. Lastly, MSM’s ability to enhance hepatic
glutathione synthesis was not affected by CRCE, a finding suggestive of its capability for mitigating
CBD/CRCE-induced hepatotoxicity. Future studies are warranted to explore this potential, as well as
the nature of long-term co-administration of CRCE with other entities.
4. Materials and Methods
4.1. CRCE Extract Characterization, Dosing Solution, and Dose Calculations
The product was prepared by extracting a CBD-rich, THC-poor Cannabis sativa L. chemovar
(commonly referred to as hemp) (5.61% of CBD and 0.2% THC w/w) using hexane as a solvent.
The ratio of CBD to THC in the extract was the same as in the plant material (28:1). The extract was
evaporated to dryness and held at 80 ◦ C for several hours in order to effect complete decarboxylation
of the phytocannabinoids.
CRCE doses were calculated to deliver the required amount of CBD. CRCE diluted in sesame
seed oil served as the final oral gavage solution. Allometric scaling for CBD mouse equivalent doses
(MEDs) was determined per the recommendation of Wojcikowski and Gobe [49], which, in turn,
is based upon an FDA Industry Guidance [50]. MEDs were based upon the recommended human
maintenance dosage of purified CBD (Epidiolex® ) as well as our previous experience with CRCE in
various animal models [13–15]. The quantity of CBD administered to a 25 g mouse (average animal
weight in this study) was 10 mg/kg/day × 12.3 (mouse allometric scaling factor) to yield a total CBD
dose of 123 mg/kg/day delivered in sesame seed oil at a total volume of 300 µL. Control mice received
300 µL of sesame seed oil.
4.2. Animals
Male C57BL6/J (7-weeks of age) were purchased from Jackson Labs (Bar Harbor, MA, USA).
Animals were acclimated for 1 week prior to study initiation and randomized into cohorts of vehicle
(sesame seed oil) and experimental groups: MSM, CRCE, and MSM/CRCE (n = 6 per group, except for
the MSM/CRCE group which contained 8 animals). Each animal was individually identified with an
ear tag. Mice were housed 3 per cage (4 animals per cage for the MSM/CRCE group) in polycarbonate
cages in an appropriate animal room at the University of Arkansas for Medical Sciences (UAMS)
Division of Laboratory Medicine from arrival until euthanasia. Room temperature was maintained at
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19–22 ◦ C with a relative humidity of 55–70%. Automatic light controls were set to provide fluorescent
lighting for a 12 h photoperiod (07:00–19:00 for light phase). All procedures were approved by the
UAMS Institutional Animal Care and Use Committee (protocol number: AUP #3902), and all personnel
followed appropriate safety precautions.
Mice received MSM (Bergstrom Nutrition, Vancouver, WA, USA) in drinking water (80 mg/100 mL)
ad libitum for 17 days. The dose of MSM chosen for this study was based on previous reports [51].
Water intake was measured frequently to ensure dosage of MSM did not differ significantly between
animals. Animals in the CRCE groups were gavaged with 123 mg/kg/day CBD (MED of 10/mg/kg/day,
a commonly used dose of CBD in clinical settings) on Monday, Tuesday, and Wednesday of Week 3
(days 15 through 17) at 08:00. All animals were scheduled to be terminated 24 h after the last gavage
treatment of the CRCE groups. Pelleted rodent diet was available ad libitum except for an overnight
fasting period prior to necropsy.
Mice were anesthetized with isoflurane and terminal bleeding was performed by a trained animal
technician. Anesthetized animals then underwent cervical dislocation to ensure death and tissues
were collected immediately. Animal body, liver, heart and kidney weights were recorded at the time
of necropsy. Livers were excised, 1-mm sections were obtained from the left and right lateral lobes,
and placed in a tissue cassette for further histological evaluation. The remaining liver tissue was
snap-frozen in liquid nitrogen and stored at −80 ◦ C for further molecular and biochemical analysis.
4.3. Histopathological Assessment
Liver sections were fixed in 4% formalin for 24 h, then briefly rinsed in PBS and stored in 70%
ethanol for 24 h. Livers were then processed at the UAMS Pathology Core Facility, stained with
hematoxylin and eosin, and evaluated by a board-certified pathologist in a blinded fashion.
For histologic assessment purposes, each liver was represented by two sections obtained from
different locations within the liver. Each section was initially evaluated at magnifications of ×40
and ×100. Sections were further evaluated at ×200 and ×400 to check for the presence of mitotic figures,
necrotic foci, and apoptotic bodies.
4.4. Blood Sampling and Clinical Biochemistry
To measure the effects of CBD extract on a panel of liver enzymes characteristic for drug-induced
liver injury, blood was collected from the retroorbital plexus with a heparinized micro-hematocrit
capillary tube (Fisher Scientific, Pittsburg, PA, USA) and placed into a 1.1-mL Z-gel microtube (Sarstedt,
Newton, NC, USA). Tubes were kept on ice and centrifuged at 10,000 rpm for 20 min; serum samples
were then immediately aliquoted and delivered to the Veterinary Diagnostic Laboratory at the Arkansas
Livestock and Poultry Commission (Little Rock, AR, USA) on dry ice where samples were processed
the same day.
4.5. miR-122 Analysis
miR-122 levels were measured in serum by qRT-PCR as previously described [52]. Briefly,
RT reactions, pre-amplification, and qRT-PCR were carried out for each sample. Two-step RT
reactions were performed in a 15 µL-RT reaction using the TaqMan miRNA Reverse Transcription Kit
(Life Technologies, Foster City, CA, USA). qRT-PCR reactions were run in 10 µL composed of 5 µL
TaqMan Universal PCR Master Mix (2×), 0.5 µL water, 0.5 µL Taqman miRNA qPCR assay (20×) and
4 µL diluted Pre-Amp products on a ViiA7 qRT-PCR thermocycler at 95 ◦ C for 10 min, 40 cycles at
95 ◦ C for 15 s and 60 ◦ C for 1 min, and held at 4 ◦ C. The miRNA expression values were normalized to
the internal control U6 and expressed as fold change according to the ∆∆Ct method.
4.6. Gene Expression
Total RNA was extracted from liver tissue using the RNeasy Mini Kit (QIAGEN, Germantown,
MD, USA) according to the manufacturer’s protocol. Following purification, 1000 ng were reverse
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transcribed with the High Capacity cDNA Reverse Transcription Kit following the manufacturer’s
instructions (Thermo Fisher, Waltham, MA, USA). Primers were added at a final concentration of 5 µM.
The list of assays used in this study can be found in Table S1. Gene expression values were normalized
to the internal control gene 18S and expressed as fold change according to the ∆∆Ct method.
4.7. Glutathione Measurement
Total glutathione (GSH + GSSG) in the liver was measured using a modified Tietze assay
as previously described [53]. Briefly, liver tissues were homogenized in 3% sulfosalicylic acid
using a bead-ruptor homogenizer. Aliquots were then diluted 50-fold in 0.01 M HCl, centrifuged,
and the deproteinated supernatants further diluted 26-fold in 100 mM potassium phosphate buffer.
Total glutathione was measured in the samples using the Tietze cycling method with glutathione
reductase and 5,5-dithio-bis-(2-nitrobenzoic acid).
4.8. Statistical Analysis
All statistical analyses were performed with the Graphpad Prism 6 software (Graphpad Software.
San Diego, CA, USA). Groups were compared with a two-way ANOVA followed by a Bonferroni
multiple comparison test when appropriate. An adjusted p-value of <0.05 was considered significant.
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